Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 202 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Psychosis and Schizophrenia Clear all
Completed No phase listed Observational Accepts healthy volunteers

Glutamate, Brain Connectivity and Duration of Untreated Psychosis

NCT02034253
View directory record Official record
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder
Interventions
Risperidone
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
17 Years to 35 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)

NCT03055338
View directory record Official record
Conditions
Schizophrenia, Acute Episode
Interventions
Elpipodect, Risperidone, Placebo matching MK-8189, Placebo matching risperidone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 29, 2026, 2:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

End Diagnostic Overshadowing

NCT06608758
View directory record Official record
Conditions
Disabilities Multiple
Interventions
Electonic health record prompts with education, Standard of care
Behavioral · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
3 Years to 89 Years
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Increasing Medication Check Participation Through Applying CT-r

NCT06231407
View directory record Official record
Conditions
Schizophrenia and Related Disorders
Interventions
Recovery Oriented CBTp Medication Management, Treatment as Usual
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia

NCT03323437
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders
Interventions
Risperidone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Glycine Pharmacodynamic Study

NCT01610011
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Glycine administration
Dietary Supplement
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Sep 29, 2026, 2:05 AM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Specialized Treatment Early in Psychosis (STEP)

NCT00309452
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features
Interventions
Cognitive Behavioral Group Therapy, Cognitive remediation, Medications, MFG, Assertive case management, Treatment as Usual in the community
Behavioral · Drug · Other
Lead sponsor
Yale University
Other
Eligibility
16 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

NCT05106309
View directory record Official record
Conditions
Schizophrenia
Interventions
10 mg CVL-231 as IR formulation, 30 mg CVL-231 as slow-release MR formulation, 30 mg CVL-231 as medium release MR formulation, 30 mg CVL-231 as fast release MR formulation, 30 mg CVL-231 Target Release, Fasted, 30 mg CVL-231 Target Release, Fed
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Psychosis

NCT02085421
View directory record Official record
Conditions
Psychosis
Interventions
tDCS
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia

NCT00601224
View directory record Official record
Conditions
Schizophrenia
Interventions
Social cognition and interaction training (SCIT), Treatment as usual (TAU)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Delta-9-THC and Iomazenil in Healthy Humans

NCT00982982
View directory record Official record
Conditions
Schizophrenia, Mental Disorders, Psychotic Disorders
Interventions
THC and Iomazenil, Placebo (control)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

NCT00361166
View directory record Official record
Conditions
Schizophrenia
Interventions
ACP-103
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Cerritos, California • Garden Grove, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2007 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders

NCT04221269
View directory record Official record
Conditions
Schizophrenia, Suicide
Interventions
Enhanced Treatment as Usual, Coping Long-term with Active Suicide Program for Schizophrenia
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 29, 2026, 2:05 AM EDT
Enrolling by invitation Phase 2 Interventional

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

NCT07459660
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MA
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
55 Years to 91 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Anaheim, California • Doral, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

NCT04092686
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856 75mg, SEP-363856 100mg, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
18
States / cities
Rogers, Arkansas • Anaheim, California • Bellflower, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 29, 2026, 2:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis

NCT01688765
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Observational
Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Sep 29, 2026, 2:05 AM EDT
Completed No phase listed Observational

Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)

NCT00246194
View directory record Official record
Conditions
Schizophrenia
Interventions
risperidone (RISPERDAL CONSTA)
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Sep 29, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

NCT03669640
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
RO6889450, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
Bellflower, California • Garden Grove, California • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis

NCT01354132
View directory record Official record
Conditions
Schizophrenic Psychoses
Interventions
n-acetylcysteine, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 4, 2017 · Synced Sep 29, 2026, 2:05 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

NCT06887192
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MA, Placebo
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 29, 2026, 2:05 AM EDT
Terminated Phase 2Phase 3 Interventional

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

NCT01908192
View directory record Official record
Conditions
Schizophrenia
Interventions
NaBen®, Placebo
Drug
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
20
States / cities
Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 29, 2026, 2:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Social Isolation and Aging in Schizophrenia

NCT07419321
View directory record Official record
Conditions
Schizophrenia and Related Disorders
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years to 70 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 29, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia

NCT03287778
View directory record Official record
Conditions
Tardive Dyskinesia, Antipsychotic Agents
Interventions
Pyridoxine, Placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 29, 2026, 2:05 AM EDT